Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health has received a warning letter from the FDA regarding promotional materials for Zenrelia™, their prescription medication for dogs. The letter addresses statements in promotional materials for the drug, which is used to control itching and inflammation associated with skin allergies in dogs over 12 months old.
The company states they are working to review and update the promotional materials as requested, while emphasizing that the warning is not related to the product's actual performance in the market. Elanco maintains its financial outlook, expecting mid-single digit organic constant currency revenue growth in 2025, and does not anticipate material impact on Zenrelia revenue.
Important safety information for Zenrelia includes warnings about vaccine-induced disease risks and the need to discontinue use 28 days to 3 months prior to vaccination. The medication carries risks of infections and neoplastic conditions, with common side effects including vomiting, diarrhea, and tiredness.
Elanco Animal Health (NYSE: ELAN) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 25, 2025. The company will host a conference call at 8:00 a.m. eastern time to discuss the results with investors, media, and the general public.
A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the call concludes.
Elanco Animal Health (NYSE: ELAN) introduces Zenrelia™, an FDA-approved once-daily oral JAK inhibitor for controlling itching associated with allergic dermatitis in dogs aged 12+ months. The treatment, launched in September 2024, addresses a significant market with approximately 17 million U.S. dogs suffering from allergic skin diseases.
A newly published study in Veterinary Dermatology compared Zenrelia to Apoquel® in over 300 allergic dogs. The medication includes a boxed warning regarding concurrent vaccine administration. Real-world cases demonstrate successful treatment outcomes, with several dogs showing significant improvement in their conditions, including reduced itching and fur regrowth.
According to a survey, 82% of pet owners with itchy dogs dream of returning to normal life with their pets. The company has launched a dedicated platform, ZenreliaForVets.com, for U.S. veterinarians to learn more and place orders.
Elanco Animal Health (NYSE: ELAN) has launched Credelio Quattro, a new monthly chewable tablet for dogs that provides six-in-one parasite protection. The product is the first of its kind to protect against tapeworms, roundworms, hookworms, heartworms, ticks, and fleas in a single tablet.
The launch marks a significant milestone as it completes Elanco's portfolio of six potential blockbuster products in the U.S. market. According to company research, 94% of dog owners prioritize proactive treatment for intestinal worms. Studies show Credelio Quattro is 100% efficacious against tapeworms and kills ticks twice as fast as competing products.
The product addresses a significant market gap, as only one-third of pet owners believe fleas and ticks are a year-round risk, and only half provide year-round heartworm protection.
Elanco Animal Health (NYSE: ELAN) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for Tuesday, January 14, 2025. Jeff Simmons, president and CEO, will represent the company and engage with analysts during a Q&A session at 3:00 p.m. PST (6:00 PM EST).
The event will be accessible through a live audio webcast on the 'Events and Presentations' section of Elanco's investor website, with a replay available for approximately 30 days following the presentation.
Elanco celebrates its annual Global Day of Purpose (GDOP) with over 150 volunteer events worldwide. During October's Global Month of Purpose, employees contributed more than 11,000 volunteer hours through various initiatives. Notable activities include: The Warsaw team building animal enrichment items for the local zoo; 500 employees at Indianapolis HQ packing 100,000 meals for Rise Against Hunger; Taiwan team removing invasive plants; Japan conducting local cleanups; and Italy supporting charities and animal shelters.
The initiative has evolved from a single day to become a year-round program, with employees participating in activities ranging from river and park cleanups to animal shelter support and environmental conservation efforts, demonstrating Elanco's commitment to improving the lives of animals, people, and the environment.
Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. Todd Young, executive vice president and CFO, will participate in:
- A fireside chat at the Evercore ISI 7th Annual HealthCONx on Tuesday, December 3, at 11:15 a.m. ET
- The Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, at 1:30 p.m. ET
Live audio webcasts will be accessible through Elanco's investor website under 'Events and Presentations,' with replays available for approximately 30 days.
Dr. Elise Kelly, a veterinarian at Elanco Animal Health, discovered the presence of potentially deadly Echinococcus tapeworms in wild animal feces in her Missouri backyard. This finding highlights a significant but often overlooked threat to both pets and humans. According to an Elanco survey, nearly half of dog owners are unaware that their pets face year-round intestinal worm risks, while 73% prefer preventive protection over reactive treatment. The company promotes Interceptor Plus, a monthly chew that protects dogs against five common types of worms, including heartworm disease, hookworm, roundworm, tapeworm, and whipworm infections.
The Schall Law Firm announces a class action lawsuit against Elanco Animal Health (NYSE:ELAN) for alleged violations of securities laws. The lawsuit covers investors who purchased securities between November 7, 2023 and June 26, 2024. The complaint alleges that Elanco made false and misleading statements about the safety of Zenrelia and overstated the timeline for launching Zenrelia and Credelio Quattro. Affected shareholders have until December 6, 2024 to join the lawsuit. The lawsuit claims investors suffered damages when the market learned the truth about these misrepresentations.
Elanco Animal Health (NYSE: ELAN) has acquired a contract manufacturing facility in Speke, UK, previously owned by TriRx Speke , which was under trading administration. The facility is important for producing farm animal product lines worth $160-180 million in annual revenue, primarily outside the U.S. The acquisition, completed for $25 million in cash, secures a critical component of Elanco's global supply chain. The company expects an adjusted EBITDA headwind of $25-35 million in 2025, mainly affecting gross profit.